Copyright Reports & Markets. All rights reserved.

Global Clinical Stage Biotechnology Market Growth (Status and Outlook) 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Clinical Stage Biotechnology Market Size 2017-2028
    • 2.1.2 Clinical Stage Biotechnology Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Clinical Stage Biotechnology Segment by Type
    • 2.2.1 Phase I
    • 2.2.2 Phase II
    • 2.2.3 Phase III
  • 2.3 Clinical Stage Biotechnology Market Size by Type
    • 2.3.1 Clinical Stage Biotechnology Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Clinical Stage Biotechnology Market Size Market Share by Type (2017-2022)
  • 2.4 Clinical Stage Biotechnology Segment by Application
    • 2.4.1 Bio-pharmaceuticals
    • 2.4.2 Scientific Research
  • 2.5 Clinical Stage Biotechnology Market Size by Application
    • 2.5.1 Clinical Stage Biotechnology Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Clinical Stage Biotechnology Market Size Market Share by Application (2017-2022)

3 Clinical Stage Biotechnology Market Size by Player

  • 3.1 Clinical Stage Biotechnology Market Size Market Share by Players
    • 3.1.1 Global Clinical Stage Biotechnology Revenue by Players (2020-2022)
    • 3.1.2 Global Clinical Stage Biotechnology Revenue Market Share by Players (2020-2022)
  • 3.2 Global Clinical Stage Biotechnology Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Clinical Stage Biotechnology by Regions

  • 4.1 Clinical Stage Biotechnology Market Size by Regions (2017-2022)
  • 4.2 Americas Clinical Stage Biotechnology Market Size Growth (2017-2022)
  • 4.3 APAC Clinical Stage Biotechnology Market Size Growth (2017-2022)
  • 4.4 Europe Clinical Stage Biotechnology Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Clinical Stage Biotechnology Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Clinical Stage Biotechnology Market Size by Country (2017-2022)
  • 5.2 Americas Clinical Stage Biotechnology Market Size by Type (2017-2022)
  • 5.3 Americas Clinical Stage Biotechnology Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Clinical Stage Biotechnology Market Size by Region (2017-2022)
  • 6.2 APAC Clinical Stage Biotechnology Market Size by Type (2017-2022)
  • 6.3 APAC Clinical Stage Biotechnology Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Clinical Stage Biotechnology by Country (2017-2022)
  • 7.2 Europe Clinical Stage Biotechnology Market Size by Type (2017-2022)
  • 7.3 Europe Clinical Stage Biotechnology Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Clinical Stage Biotechnology by Region (2017-2022)
  • 8.2 Middle East & Africa Clinical Stage Biotechnology Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Clinical Stage Biotechnology Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Clinical Stage Biotechnology Market Forecast

  • 10.1 Global Clinical Stage Biotechnology Forecast by Regions (2023-2028)
    • 10.1.1 Global Clinical Stage Biotechnology Forecast by Regions (2023-2028)
    • 10.1.2 Americas Clinical Stage Biotechnology Forecast
    • 10.1.3 APAC Clinical Stage Biotechnology Forecast
    • 10.1.4 Europe Clinical Stage Biotechnology Forecast
    • 10.1.5 Middle East & Africa Clinical Stage Biotechnology Forecast
  • 10.2 Americas Clinical Stage Biotechnology Forecast by Country (2023-2028)
    • 10.2.1 United States Clinical Stage Biotechnology Market Forecast
    • 10.2.2 Canada Clinical Stage Biotechnology Market Forecast
    • 10.2.3 Mexico Clinical Stage Biotechnology Market Forecast
    • 10.2.4 Brazil Clinical Stage Biotechnology Market Forecast
  • 10.3 APAC Clinical Stage Biotechnology Forecast by Region (2023-2028)
    • 10.3.1 China Clinical Stage Biotechnology Market Forecast
    • 10.3.2 Japan Clinical Stage Biotechnology Market Forecast
    • 10.3.3 Korea Clinical Stage Biotechnology Market Forecast
    • 10.3.4 Southeast Asia Clinical Stage Biotechnology Market Forecast
    • 10.3.5 India Clinical Stage Biotechnology Market Forecast
    • 10.3.6 Australia Clinical Stage Biotechnology Market Forecast
  • 10.4 Europe Clinical Stage Biotechnology Forecast by Country (2023-2028)
    • 10.4.1 Germany Clinical Stage Biotechnology Market Forecast
    • 10.4.2 France Clinical Stage Biotechnology Market Forecast
    • 10.4.3 UK Clinical Stage Biotechnology Market Forecast
    • 10.4.4 Italy Clinical Stage Biotechnology Market Forecast
    • 10.4.5 Russia Clinical Stage Biotechnology Market Forecast
  • 10.5 Middle East & Africa Clinical Stage Biotechnology Forecast by Region (2023-2028)
    • 10.5.1 Egypt Clinical Stage Biotechnology Market Forecast
    • 10.5.2 South Africa Clinical Stage Biotechnology Market Forecast
    • 10.5.3 Israel Clinical Stage Biotechnology Market Forecast
    • 10.5.4 Turkey Clinical Stage Biotechnology Market Forecast
    • 10.5.5 GCC Countries Clinical Stage Biotechnology Market Forecast
  • 10.6 Global Clinical Stage Biotechnology Forecast by Type (2023-2028)
  • 10.7 Global Clinical Stage Biotechnology Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Minoryx
    • 11.1.1 Minoryx Company Information
    • 11.1.2 Minoryx Clinical Stage Biotechnology Product Offered
    • 11.1.3 Minoryx Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Minoryx Main Business Overview
    • 11.1.5 Minoryx Latest Developments
  • 11.2 Inhibrx
    • 11.2.1 Inhibrx Company Information
    • 11.2.2 Inhibrx Clinical Stage Biotechnology Product Offered
    • 11.2.3 Inhibrx Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Inhibrx Main Business Overview
    • 11.2.5 Inhibrx Latest Developments
  • 11.3 NovaBiotics
    • 11.3.1 NovaBiotics Company Information
    • 11.3.2 NovaBiotics Clinical Stage Biotechnology Product Offered
    • 11.3.3 NovaBiotics Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 NovaBiotics Main Business Overview
    • 11.3.5 NovaBiotics Latest Developments
  • 11.4 RadioMedix
    • 11.4.1 RadioMedix Company Information
    • 11.4.2 RadioMedix Clinical Stage Biotechnology Product Offered
    • 11.4.3 RadioMedix Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 RadioMedix Main Business Overview
    • 11.4.5 RadioMedix Latest Developments
  • 11.5 Artax Biopharma
    • 11.5.1 Artax Biopharma Company Information
    • 11.5.2 Artax Biopharma Clinical Stage Biotechnology Product Offered
    • 11.5.3 Artax Biopharma Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Artax Biopharma Main Business Overview
    • 11.5.5 Artax Biopharma Latest Developments
  • 11.6 Ribon Therapeutics
    • 11.6.1 Ribon Therapeutics Company Information
    • 11.6.2 Ribon Therapeutics Clinical Stage Biotechnology Product Offered
    • 11.6.3 Ribon Therapeutics Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Ribon Therapeutics Main Business Overview
    • 11.6.5 Ribon Therapeutics Latest Developments
  • 11.7 Brickell Biotech
    • 11.7.1 Brickell Biotech Company Information
    • 11.7.2 Brickell Biotech Clinical Stage Biotechnology Product Offered
    • 11.7.3 Brickell Biotech Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Brickell Biotech Main Business Overview
    • 11.7.5 Brickell Biotech Latest Developments
  • 11.8 Coave Therapeutics
    • 11.8.1 Coave Therapeutics Company Information
    • 11.8.2 Coave Therapeutics Clinical Stage Biotechnology Product Offered
    • 11.8.3 Coave Therapeutics Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Coave Therapeutics Main Business Overview
    • 11.8.5 Coave Therapeutics Latest Developments
  • 11.9 Edesa Biotech
    • 11.9.1 Edesa Biotech Company Information
    • 11.9.2 Edesa Biotech Clinical Stage Biotechnology Product Offered
    • 11.9.3 Edesa Biotech Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 Edesa Biotech Main Business Overview
    • 11.9.5 Edesa Biotech Latest Developments
  • 11.10 CellCentric
    • 11.10.1 CellCentric Company Information
    • 11.10.2 CellCentric Clinical Stage Biotechnology Product Offered
    • 11.10.3 CellCentric Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 CellCentric Main Business Overview
    • 11.10.5 CellCentric Latest Developments
  • 11.11 LimmaTech Biologics AG
    • 11.11.1 LimmaTech Biologics AG Company Information
    • 11.11.2 LimmaTech Biologics AG Clinical Stage Biotechnology Product Offered
    • 11.11.3 LimmaTech Biologics AG Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.11.4 LimmaTech Biologics AG Main Business Overview
    • 11.11.5 LimmaTech Biologics AG Latest Developments
  • 11.12 Adaptive Phage Therapeutics
    • 11.12.1 Adaptive Phage Therapeutics Company Information
    • 11.12.2 Adaptive Phage Therapeutics Clinical Stage Biotechnology Product Offered
    • 11.12.3 Adaptive Phage Therapeutics Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.12.4 Adaptive Phage Therapeutics Main Business Overview
    • 11.12.5 Adaptive Phage Therapeutics Latest Developments
  • 11.13 Intra-ImmuSG
    • 11.13.1 Intra-ImmuSG Company Information
    • 11.13.2 Intra-ImmuSG Clinical Stage Biotechnology Product Offered
    • 11.13.3 Intra-ImmuSG Clinical Stage Biotechnology Revenue, Gross Margin and Market Share (2020-2022)
    • 11.13.4 Intra-ImmuSG Main Business Overview
    • 11.13.5 Intra-ImmuSG Latest Developments

12 Research Findings and Conclusion

As the global economy mends, the 2021 growth of Clinical Stage Biotechnology will have significant change from previous year. According to our (LP Information) latest study, the global Clinical Stage Biotechnology market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Clinical Stage Biotechnology market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.

The United States Clinical Stage Biotechnology market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Clinical Stage Biotechnology market, reaching US$ million by the year 2028. As for the Europe Clinical Stage Biotechnology landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.

Global main Clinical Stage Biotechnology players cover Minoryx, Inhibrx, NovaBiotics, and RadioMedix, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Clinical Stage Biotechnology market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Phase I
Phase II
Phase III

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Bio-pharmaceuticals
Scientific Research

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Minoryx
Inhibrx
NovaBiotics
RadioMedix
Artax Biopharma
Ribon Therapeutics
Brickell Biotech
Coave Therapeutics
Edesa Biotech
CellCentric
LimmaTech Biologics AG
Adaptive Phage Therapeutics
Intra-ImmuSG
Buy now